5.4 Fractional Continual Reassessment Method
Most of the dose-finding methods, including the aforementioned CRM and BMA-CRM, require the DLT outcomes to be ascertainable shortly after treatment. In other words, the toxicity outcomes of all the previously treated patients must be available in order to determine the next dose assignment. However, it may take a long period of time to measure the DLT outcomes after treatment. In a more common scenario, if the patient accrual is fast and the toxicity measurements cannot keep pace with the enrollment, missing toxicity data arise as the outcomes of the patients under treatment may still be unavailable when that information is needed. For example, in radiotherapy trials, DLTs often occur long after the ...
Get Modern Approaches to Clinical Trials Using SAS: Classical, Adaptive, and Bayesian Methods now with the O’Reilly learning platform.
O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.
